Samer Srour, MB ChB, MS, on Proof-of-Concept of Allogeneic CAR T in Renal Cell Carcinoma

Video

The assistant professor of stem cell transplantation at MD Anderson Cancer Center discussed updated data on ALLO-316 in patients with ccRCC.

“The biggest highlights from the study are that we did not see any unexpected safety signals and we have seen very encouraging results for being an early phase study at very low dose levels... This is a proof of concept that we can do something for solid tumors since there's a lot of challenges using CAR T-cell treatments."

ALLO-316, Allogene Therapeutics’ allogeneic chimeric antigen receptor (CAR) T-cell therapy, demonstrated antitumor activity with a manageable safety profile in participants with advanced or metastatic CD70+ clear cell renal cell carcinoma (ccRCC), according to updated data in the phase 1 TRAVERSE study (NCT04696731) presented by Samer Srour, MB ChB, MS, assistant professor, stem cell transplantation, MD Anderson Cancer Center, at the American Associated for Cancer Research (AACR) Annual Meeting 2023, held April 14-19 in Orlando, Florida.

CGTLive™’s sister site, OncLive™, spoke with Srour to learn more about ALLO-316 and the updated data, including an overall response rate of 17% (30% in patients with confirmed CD70+ tumors) and a disease control rate of 89%; mostly mild cytokine release syndrome cases, and a single dose-limiting toxicity of grade 3 type 2 autoimmune hepatitis. He also discussed the importance of the trial as a proof-of-concept for allogeneic CAR T-cell therapy in treating solid tumors, a field that has posed many challenges to the use of traditional CAR T-cell therapies.


Click here to read more coverage of the AACR 2023 Annual Meeting.

REFERENCE
Srour S, Kotecha R, Curti B, et al. A phase 1 multicenter study (TRAVERSE) evaluating the safety and efficacy of ALLO-316 following conditioning regimen in pts with advanced or metastatic clear cell renal cell carcinoma (ccRCC). Presented at: AACR Annual Meeting 2023, April 14-19; Orlando, Florida. Abstract #CT011
Related Videos
Caspian Oliai, MD, MS, the medical director of the UCLA Bone Marrow Transplantation Stem Cell Processing Center
Frederick “Eric” Arnold, PhD
Genovefa (Zenia) Papanicolaou, MD, an infectious diseases specialist at Memorial Sloan Kettering Cancer Center
Jeffrey Chamberlain, PhD, on Exciting New Research at MDA 2024
Alan Beggs, PhD, on Challenges in Therapeutic Development for Rare Diseases
Akshay Sharma, MBBS, a bone marrow transplant physician at St. Jude Children’s Research Hospital
PJ Brooks, PhD
John DiPersio, MD, PhD, the director of the Center for Gene and Cellular Immunotherapy at Washington University School of Medicine
Carlos Moraes, PhD, on Understanding Mitochondrial Mutations for Neurodegenerative Diseases
Aude Chapuis, MD, an associate professor in the Translational Science and Therapeutics Division at Fred Hutch Cancer Center
© 2024 MJH Life Sciences

All rights reserved.